Vertex Pharmaceuticals Incorporated VRTX
At closeNov 3, 2026, 7:36 PM EST
After hours · Nov 3, 7:36 PM ET
- YTD
- +17.07%
- 1 year
- +24.59%
- Market cap
- 134.53B
- Revenue (ttm)
- 12.59B
- Profit margin
- 35.00%
- EPS (ttm)
- 15.54
- Shares out
- 253.46M
- P/E ratio
- 34.15
- Forward P/E
- 25.99
- YTD return
- +17.07%
- 1-year return
- +24.59%
- Volume
- 2.37M
- Avg volume
- 1.22M
- Open
- 558.44
- Previous close
- 553.15
- Day's range
- 529.15 – 561.96
- 52-week range
- 403.16 – 568.67
- Beta
- 0.28
- Analysts
- Buy
- Price target
- 576.29 (+8.6%)
- Earnings date
- Feb 11, 2027
5D +14.84 (+2.87%)
Key statistics
- Enterprise value
- 134.33B
- PEG ratio
- 2.16
- Price / sales
- 10.69
- Price / book
- 6.64
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 12.50%
- Free cash flow
- 2.63B
- Total cash
- 7.85B
- Total debt
- 1.98B
- Return on equity
- 23.54%
- Short % of float
- 1.90%
- 50-day average
- 523.32
- 200-day average
- 479.79
Analyst view
Consensus: buy
- Target (low)
- 350.00
- Target (mean)
- 576.29
- Target (high)
- 725.00
- Strong buy6
- Buy20
- Hold4
- Sell1
- Strong sell1
Next earnings
Feb 11, 2027
Expected Feb 11, 2027. Consensus EPS estimate 4.78.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 11, 2027 | Dec 30, 2026 | 4.64 | — | — | — |
| Nov 2, 2026 | Sep 30, 2026 | 4.82 | 4.76 | -0.06 | -1.24% |
| Aug 3, 2026 | Jun 30, 2026 | 4.74 | 4.73 | -0.01 | -0.21% |
| May 4, 2026 | Mar 31, 2026 | 4.24 | 4.47 | +0.23 | +5.42% |
| Feb 12, 2026 | Dec 31, 2025 | 5.11 | 5.03 | -0.08 | -1.57% |
| Nov 3, 2025 | Sep 30, 2025 | 4.57 | 4.80 | +0.23 | +5.03% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 3, 2026 | JP Morgan | main | Overweight | Overweight |
| Nov 3, 2026 | Goldman Sachs | main | Buy | Buy |
| Nov 3, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Nov 3, 2026 | Scotiabank | main | Sector Outperform | Sector Outperform |
| Nov 3, 2026 | UBS | main | Buy | Buy |
| Nov 3, 2026 | TD Cowen | main | Buy | Buy |
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- vrtx.com
News
Goldman Sachs Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $725
Morgan Stanley Maintains Overweight on Vertex Pharmaceuticals, Lowers Price Target to $660
Scotiabank Maintains Sector Outperform on Vertex Pharmaceuticals, Raises Price Target to $660
CRSP's Q3 Loss Wider Than Expected, Sales Beat Estimates UBS Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $640
VRTX's Q3 Earnings Lag Estimates, Revenues Top, 2026 Sales View Raised TD Cowen Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $575
Wells Fargo Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $650
RBC Capital Maintains Outperform on Vertex Pharmaceuticals, Raises Price Target to $600
Apple To $350? Here Are 10 Top Analyst Forecasts For Tuesday
Your note
Sign in to keep a note on VRTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALTSHULER DAVID | Officer | Stock Award(Grant) | Jan 21, 2026 | 34,477 |
| ARBUCKLE STUART A | Chief Operating Officer | Stock Award(Grant) | May 12, 2025 | 100,751 |
| ATKINSON EDWARD MORROW III | Chief Technology Officer | Sale | Feb 24, 2026 | 18,432 |
| KEWALRAMANI RESHMA | Chief Executive Officer | Sale | Feb 26, 2026 | 98,278 |
| LEIDEN JEFFREY M | Officer and Director | Stock Award(Grant) | Feb 16, 2026 | 38,784 |
| LIU JOY | Officer | Sale | Jun 30, 2026 | 19,131 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Capital World Investors | 10.29% | 26,115,014 | 13.86B | Jun 29, 2026 |
| Blackrock Inc. | 9.50% | 24,109,373 | 12.80B | Jun 29, 2026 |
| Capital Research Global Investors | 7.68% | 19,490,637 | 10.34B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 6.53% | 16,580,713 | 8.80B | Jun 29, 2026 |
| State Street Corporation | 4.68% | 11,871,459 | 6.30B | Jun 29, 2026 |
| Invesco Ltd. | 3.17% | 8,043,052 | 4.27B | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Growth Fund of America | 5.09% | 12,908,237 | 6.85B | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.17% | 8,058,128 | 4.28B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.59% | 6,576,510 | 3.49B | Jun 29, 2026 |
| AMERICAN BALANCED FUND | 2.14% | 5,428,865 | 2.88B | Sep 29, 2026 |
| Invesco QQQ Trust, Series 1 | 2.09% | 5,294,126 | 2.81B | Sep 29, 2026 |
| Amcap Fund | 1.87% | 4,734,921 | 2.51B | Sep 29, 2026 |
